Population-based Respiratory Syncytial Virus Hospitalization Disease Burden and Cost Effectiveness of Palivizumab Prophylaxis in Infants with Hemodynamically Significant Congenital Heart Diseases

Robin Hay-son Chen* , Susan Shui-seng Chiu, So-lun Lee, Tak-Cheung Yung.

  • Name: Robin Hay-son Chen*
  • Phone: +852 35136335
  • Country: Hong Kong
  • Received date: 22 March, 2021
  • Accepted date: 22 September, 2021
  • Published date: 29 September, 2021

Designation: Department of Pediatrics and Adolescent Medicine, Cardiology Unit, Hong Kong Children’s Hospital, Hong Kong SAR

Citation: Chen RHS, Chiu SSS, Lee SL, Yung TC (2021) Population-based Respiratory Syncytial Virus Hospitalization Disease Burden and Cost Effectiveness of Palivizumab Prophylaxis in Infants with Hemodynamically Significant Congenital Heart Diseases. J Pediat Infants Vol: 4, Issu: 2 (48-55).

Copyright: 2021 Chen RHS et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Fulltext Under Construction
Facebook
Twitter
LinkedIn